Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

C. Maroun · SciRah

Researcher profile · Semantic Scholar

C. Maroun

Share profile

C. Maroun — researcher profile on SciRah

h-index: 17
Works: 48
Citations: 2,259

Most-cited papers

Death of mature T cells by separate ligation of CD4 and the T-cell receptor for antigen
M. Newell, Lori Haughn, C. Maroun, M. Julius
1990Nature392 citations
Semantic Scholar
The Tyrosine Phosphatase SHP-2 Is Required for Sustained Activation of Extracellular Signal-Regulated Kinase and Epithelial Morphogenesis Downstream from the Met Receptor Tyrosine Kinase
C. Maroun, M. Naujokas, Marina Holgado-Madruga, A. Wong +1 more
2000Molecular and Cellular Biology299 citations Open access
Semantic Scholar
Distinct roles for CD4 and CD8 as co-receptors in antigen receptor signalling.
M. Julius, C. Maroun, L. Haughn
1993Immunology today (Amsterdam. Regular ed.)267 citations
Semantic Scholar
The Gab1 PH Domain Is Required for Localization of Gab1 at Sites of Cell-Cell Contact and Epithelial Morphogenesis Downstream from the Met Receptor Tyrosine Kinase
C. Maroun, Marina Holgado-Madruga, I. Royal, M. Naujokas +3 more
1999Molecular and Cellular Biology205 citations Open access
Semantic Scholar
The Met receptor tyrosine kinase: a key player in oncogenesis and drug resistance.
C. Maroun, Tracey M. Rowlands
2014Pharmacology and Therapeutics199 citations
Semantic Scholar
Association of the Multisubstrate Docking Protein Gab1 with the Hepatocyte Growth Factor Receptor Requires a Functional Grb2 Binding Site Involving Tyrosine 1356*
L. Nguyễn, Marina Holgado-Madruga, C. Maroun, E. Fixman +6 more
1997Journal of Biological Chemistry168 citations Open access
Semantic Scholar
Novel HDAC6 isoform selective chiral small molecule histone deacetylase inhibitors.
D. Smil, S. Manku, Y. Chantigny, S. Leit +12 more
2009Bioorganic & Medicinal Chemistry Letters85 citations Open access
Semantic Scholar
A Conserved Inositol Phospholipid Binding Site within the Pleckstrin Homology Domain of the Gab1 Docking Protein Is Required for Epithelial Morphogenesis*
C. Maroun, D. Moscatello, M. Naujokas, Marina Holgado-Madruga +2 more
1999Journal of Biological Chemistry84 citations Open access
Semantic Scholar
Histone deacetylase inhibitors: latest developments, trends and prospects.
O. Moradei, C. Maroun, I. Paquin, A. Vaisburg
2005Current Medicinal Chemistry - Anti-Cancer Agents74 citations
Semantic Scholar
The Gab1 Docking Protein Links the B Cell Antigen Receptor to the Phosphatidylinositol 3-Kinase/Akt Signaling Pathway and to the SHP2 Tyrosine Phosphatase*
R. Ingham, L. Santos, M. Dang-Lawson, Marina Holgado-Madruga +5 more
2001Journal of Biological Chemistry73 citations Open access
Semantic Scholar
Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers
E. Linklater, Elizabeth A. Tovar, Curt J. Essenburg, L. Turner +9 more
2016OncoTarget66 citations Open access
Semantic Scholar
Distinct recruitment and function of Gab1 and Gab2 in Met receptor-mediated epithelial morphogenesis.
Lisa S Lock, C. Maroun, M. Naujokas, Morag Park
2002Molecular Biology of the Cell58 citations Open access
Semantic Scholar
Enhanced Transformation by a Plasma Membrane-Associated Met Oncoprotein: Activation of a Phosphoinositide 3′-Kinase-Dependent Autocrine Loop Involving Hyaluronic Acid and CD44
D. Kamikura, Hanane Khoury, C. Maroun, M. Naujokas +1 more
2000Molecular and Cellular Biology53 citations Open access
Semantic Scholar
Membrane targeting of Grb2-associated binder-1 (Gab1) scaffolding protein through Src myristoylation sequence substitutes for Gab1 pleckstrin homology domain and switches an epidermal growth factor response to an invasive morphogenic program.
C. Maroun, M. Naujokas, Morag Park
2003Molecular Biology of the Cell33 citations Open access
Semantic Scholar
Cbl-transforming variants trigger a cascade of molecular alterations that lead to epithelial mesenchymal conversion.
Tanya M. Fournier, L. Lamorte, C. Maroun, M. Lupher +3 more
2000Molecular Biology of the Cell33 citations Open access
Semantic Scholar
Phase I/II Study of MGCD0103, an Oral Isotype-Selective Histone Deacetylase (HDAC) Inhibitor, in Combination with 5-Azacitidine in Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML).
G. Garcia-Manero, A. Yang, V. Klimek, J. Cortes +10 more
200725 citations
Semantic Scholar
Identification of a novel series of potent RON receptor tyrosine kinase inhibitors.
S. Raeppel, F. Gaudette, M. Mannion, S. Claridge +12 more
2010Bioorganic & Medicinal Chemistry Letters20 citations Open access
Semantic Scholar
Phase I study of daily administration of MGCD265 to patients with advanced malignancies (Study 265-101).
C. Kollmannsberger, H. Hurwitz, G. Vlahović, C. Maroun +4 more
2009Journal of Clinical Oncology17 citations
Semantic Scholar
Ospemifene versus local estrogen: adherence and costs in postmenopausal dyspareunia.
B. Faught, G. Soulban, J. Yeaw, C. Maroun +3 more
2019Journal of Comparative Effectiveness Research16 citations
Semantic Scholar
Abstract 1790: The combination of MGCD265, a Met/VEGFR inhibitor in clinical development, and erlotinib potently inhibits tumor growth by altering multiple pathways including glycolysis
C. Bonfils, N. Beaulieu, M. Fournel, H. Ste-Croix +2 more
201216 citations
Semantic Scholar
Pharmacodynamic effect of MGCD0103, an oral isotype-selective histone deacetylase (HDAC) inhibitor, on HDAC enzyme inhibition and histone acetylation induction in phase I clinical trials in patients (pts) with advanced solid tumors or non-Hodgkin’s lymphoma (NHL)
Ann Kalita, C. Maroun, C. Bonfils, K. Gelmon +6 more
200512 citations
Semantic Scholar
Functional consequences of CD4-TCR/CD3 interactions.
Michael Julius, K. Newell, C. Maroun, L. Haughn
1991Seminars in Immunology11 citations
Semantic Scholar
Phase I/II study of a novel oral isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 in combination with azacitidine in patients (pts) with high-risk myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML)
G. Garcia-Manero, A. Yang, V. Klimek, S. Luger +7 more
20079 citations
Semantic Scholar
MGCD265, a multitargeted oral tyrosine kinase receptor inhibitor of Met and VEGFR, in combination with docetaxel.
M. Beeram, A. Patnaik, R. Amaravadi, N. Haas +15 more
20126 citations
Semantic Scholar
MGCD265, an oral Met/VEGFR multitargeted receptor tyrosine kinase inhibitor, in combination with erlotinib: Phase I clinical experience.
P. O'Dwyer, K. Papadopoulos, A. Tolcher, U. Teitelbaum +12 more
2011Journal of Clinical Oncology6 citations
Semantic Scholar
Abstract 930: Preclinical characterization of MG516, a novel inhibitor of receptor tyrosine kinases involved in resistance to targeted therapies.
N. Beaulieu, H. Sainte-Croix, C. Bonfils, M. Mannion +10 more
20135 citations
Semantic Scholar
Identification of a Novel Series of Potent TrkA Receptor Tyrosine Kinase Inhibitors
S. Raeppel, F. Gaudette, Hannah Nguyen, N. Beaulieu +4 more
2012International Journal of Medicinal Chemistry4 citations Open access
Semantic Scholar
312 A Novel Assay for the Met Inhibitory Activity of MGCD265 in Plasma From Solid Tumor Patients in a Dose Escalating Phase I Study
M. Fournel, James Wang, N. Beaulieu, C. Bonfils +6 more
20124 citations
Semantic Scholar
The Gab 1 Docking Protein Links the B Cell Antigen Receptor to the Phosphatidylinositol 3-Kinase / Akt Signaling Pathway and to the SHP 2 Tyrosine Phosphatase *
R. Ingham, L. Santos, M. Dang-Lawson, Marina Holgado-Madruga +5 more
20014 citations
Semantic Scholar
MGCD265, a multitargeted oral tyrosine kinase receptor inhibitor of Met and VEGFR, in combination with erlotinib in patients with advanced solid tumors.
P. O'Dwyer, K. Papadopoulos, A. Tolcher, U. Teitelbaum +14 more
20123 citations
Semantic Scholar
395 MGCD265, an orally active Met/VEGFR multitargeted kinase inhibitor, in combination with erlotinib: clinical and preclinical experience
A. Patnaik, J. Besterman, A. Tolcher, M. Mehran +6 more
20103 citations
Semantic Scholar
Abstract 3612: Potent preclinical anti-tumor activity of MGCD265, an orally active Met/VEGFR multitargeted kinase inhibitor in Phase II clinical development, in combination with an EGFR inhibitor
M. Fournel, I. Dupont, C. Bonfils, M. Dubay +15 more
20103 citations
Semantic Scholar
Determination of the maximum tolerated dose (MTD) of MGCD265, an oral Met/VEGFR multitargeted receptor tyrosine kinase inhibitor, in combination with docetaxel.
D. Rasco, A. Patnaik, R. Amaravadi, K. Papadopoulos +13 more
2011Journal of Clinical Oncology2 citations
Semantic Scholar
Phase I study of daily administration of MGCD265 to patients with advanced malignancies (Study 265–101)
C. Kollmannsberger, H. Hurwitz, G. Vlahović, C. Maroun +4 more
20092 citations
Semantic Scholar
81 POSTER Preclinical pharmacodynamic markers of MGCD265, a potent orally active c-Met/VEGFR multitargeted kinase inhibitor in Phase I clinical trials
N. Beaulieu, I. Dupont, Carole Beaulieu, Hannah Nguyen +6 more
20082 citations
Semantic Scholar
MGCD265, a multitargeted oral tyrosine kinase receptor inhibitor of Met and VEGFR: Dose-escalation phase I study.
C. Kollmannsberger, H. Hurwitz, J. Cleary, J. Strickler +11 more
20121 citations
Semantic Scholar
017 Evaluation of Vulvar Health from Photographs in a Multicenter, Randomized, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of Ospemifene in 631 Postmenopausal Women (age 40-80) with Moderate to Severe Vaginal Dryness
I. Goldstein, J. Simon, A. Kaunitz, C. Altomare +3 more
2019Journal of Sexual Medicine0 citations
Semantic Scholar
094 Phase III Study Evaluating Efficacy and Safety of Ospemifene in Menopausal Women with Moderate to Severe Vaginal Dryness: Overall Patient Satisfaction with Treatment
J. Simon, I. Goldstein, S. Goldstein, C. Altomare +3 more
2019Journal of Sexual Medicine0 citations
Semantic Scholar
A Phase I, Dose-Escalation Study of Mgcd265, A Multi-Targeted Oral Tyrosine Kinase Receptor Inhibitor, for Treatment of Advanced Solid Tumors
H. Hurwitz, C. Kollmannsberger, M. Juretic, J. Wang +6 more
20120 citations Open access
Semantic Scholar
Clinical Effects of MGCD265, an oral Tyrosine Kinase Inhibitor, in Combination with Erlotinib or Docetaxel for Treatment of Advanced Gastroesophageal and Nsclc Tumors
A. Patnaik, K. Papadopoulos, A. Tolcher, M. Beeram +6 more
20120 citations Open access
Semantic Scholar
Pharmacokinetic Profile of MGCD265, an Oral Tyrosine Kinase Inhibitor, with or Without Food in Healthy Volunteers
É. Sicard, M. Juretic, M. Drouin, G. Reid +4 more
20120 citations Open access
Semantic Scholar
Abstract 3610: Potent preclinical anti-tumor activity of MGCD265, an oral Met/VEGFR multitargeted kinase inhibitor in clinical development, in combination with taxanes
C. Maroun, H. Ste-Croix, N. Beaulieu, C. Bonfils +5 more
20110 citations
Semantic Scholar
Abstract A95: The determination of the maximum tolerated dose (MTD) of MGCD265 on an intermittent schedule: Phase I study results (Study 265-102).
J. Wheler, R. Kurzrock, E. Heath, G. Falchook +8 more
20110 citations
Semantic Scholar
Abstract 3609: MGCD265, an orally active Met/VEGFR multitargeted kinase inhibitor in Phase II clinical development, potently inhibits clinically relevant Met mutants
N. Beaulieu, I. Dupont, C. Bonfils, M. Dubay +10 more
20100 citations
Semantic Scholar
Abstract B51: A phase I dose‐escalation study of MGCD265 in patients with advanced malignancies (study 265‐102)
P. LoRusso, R. Kurzrock, A. Weise, E. Heath +8 more
20090 citations
Semantic Scholar
Niemann-Pick Disease, A Rare Cause of Hepatomegaly and Failure to Thrive in Infancy: 834
S. Nanton, C. Maroun, R. Sulaiman, Lynn Nanton +2 more
20090 citations
Semantic Scholar
Involving Hyaluronic Acid and CD 44-Kinase-Dependent Autocrine Loop ′ Activation of a Phosphoinositide 3 Membrane-Associated Met Oncoprotein : Enhanced Transformation by a Plasma
M. Naujokas, Morag Park, D. Kamikura, Hanane Khoury +1 more
20000 citations
Semantic Scholar
Distinct mechanisms regulate antigen receptor mediated signalling in CD4+ and CD8+ primary T cells
C. Maroun, M. Julius
19950 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

J. Besterman×22
Invite
J. Besterman — researcher profile on SciRah
C. Bonfils×12
Invite
C. Bonfils — researcher profile on SciRah
M. Fournel×11
Invite
M. Fournel — researcher profile on SciRah
Morag Park×9
Invite
Morag Park — researcher profile on SciRah

×9

Invite

N. Beaulieu — researcher profile on SciRah

Invite

M. Drouin — researcher profile on SciRah

Invite

James Wang — researcher profile on SciRah

Invite

M. Naujokas — researcher profile on SciRah

Invite

A. Vaisburg — researcher profile on SciRah

Invite

R. Martell — researcher profile on SciRah

Invite

A. Tolcher — researcher profile on SciRah

Invite

M. Mehran — researcher profile on SciRah